The anti-PD-L1 mAb atezolizumab as a first-line single-agent also achieved a 17% ORR in patients with advanced HCC in the phase Ib GO30140 study (Lee et al., 2020). The gene discussed is CD274; the disease is hepatocellular carcinoma.